Covid-19
Britain investigates AstraZeneca-Alexion deal on competition concerns
Britain’s Competition and Markets Authority (CMA) has started its investigation into whether AstraZeneca’s takeover of Alexion Pharmaceuticals can reduce competition for products and services in the United Kingdom or any other markets.
The British competition regulator invites comments on the transaction from any interested party to assist the CMA with the assessment.
The comments should be reached by June 3.
In December 2020, British drug manufacturer AstraZeneca agreed to buy Alexion Pharmaceuticals for 175 dollars per share in cash and stock, valuing the Boston-based company at 39 billion dollars.
-
Business6 days agoDisCos urge Minister to end blame game, apologise to Nigerians over blackouts
-
Health1 week agoStudy links Pfizer COVID-19 vaccine to higher death rates than Moderna shot
-
Business1 week agoPower supply to improve in 72 hours as FG moves to restore generation – Tegbe
-
Business5 days agoFuel price: Our eyes on you, FCCPC tells oil marketers
-
Football6 days agoFlamingos arrive in Abuja after historic U-17 Women’s World Cup victory
-
Business6 days agoAfter weeks of blackout, electricity returns to Lagos, Ogun, Oyo, Kwara, FCT
-
Latest6 days agoAbati questions former CSU lecturer’s authority in fresh Tinubu certificate dispute [VIDEO]
-
Football1 week agoBernardo Silva Succeeds Ronaldo as Portugal Captain